Get Premium to unlock powerful stock data

Top 5 1st Quarter Trades of Atlas Venture Advisors, Inc.

Author's Avatar
insider
May 12, 2022
Article's Main Image

Atlas Venture Advisors, Inc. recently filed their 13F report for the first quarter of 2022, which ended on 2022-03-31.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

46 Wareham Street BOSTON, MA 02118

As of the latest 13F report, the guru’s equity portfolio contained 7 stocks valued at a total of $464,000,000. The top holdings were IAS(67.53%), DKNG(27.49%), and SNAP(1.90%).

According to GuruFocus data, these were Atlas Venture Advisors, Inc.’s top five trades of the quarter.

Bicycle Therapeutics PLC


The guru sold out of their 307,696-share investment in NAS:BCYC. Previously, the stock had a 1.52% weight in the equity portfolio. Shares traded for an average price of $55.41 during the quarter.

On 05/12/2022, Bicycle Therapeutics PLC traded for a price of $16.64 per share and a market cap of $512,225,000. The stock has returned -46.05% over the past year.

GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Bicycle Therapeutics PLC has a price-book ratio of 1.59, a EV-to-Ebitda ratio of -2.11 and a price-sales ratio of 34.59.

The price-to-GF Value ratio is 1.06, earning the stock a GF Value rank of 3.

Translate Bio Inc


The guru sold out of their 1,872,115-share investment in NAS:TBIO. Previously, the stock had a 5.35% weight in the equity portfolio. Shares traded for an average price of $34.42 during the quarter.

On 05/12/2022, Translate Bio Inc traded for a price of $37.36 per share and a market cap of $2,823,920,000. The stock has returned 165.91% over the past year.

There is insufficient data to calculate the stock’s financial strength and profitability ratings.

In terms of valuation, Translate Bio Inc has a price-earnings ratio of 73.83, a price-book ratio of 6.82, a EV-to-Ebitda ratio of 42.75 and a price-sales ratio of 12.87.

DraftKings Inc


Atlas Venture Advisors, Inc. reduced their investment in NAS:DKNG by 728,400 shares. The trade had a 3.94% impact on the equity portfolio. During the quarter, the stock traded for an average price of $53.1.

On 05/12/2022, DraftKings Inc traded for a price of $11.37 per share and a market cap of $5,902,651,000. The stock has returned -76.66% over the past year.

GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, DraftKings Inc has a price-book ratio of 3.29, a EV-to-Ebitda ratio of -3.65 and a price-sales ratio of 4.18.

Integral Ad Science Holding Corp


The guru established a new position worth 22,722,770 shares in NAS:IAS, giving the stock a 48.54% weight in the equity portfolio. Shares traded for an average price of $20.58 during the quarter.

On 05/12/2022, Integral Ad Science Holding Corp traded for a price of $11.32 per share and a market cap of $2,070,631,000. The stock has returned 0.00% over the past year.

GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 2 out of 10.

In terms of valuation, Integral Ad Science Holding Corp has a price-book ratio of 2.49, a EV-to-Ebitda ratio of 83.16 and a price-sales ratio of 5.63.

F-star Therapeutics Inc


The guru established a new position worth 574,996 shares in NAS:FSTX, giving the stock a 1.15% weight in the equity portfolio. Shares traded for an average price of $9.72 during the quarter.

On 05/12/2022, F-star Therapeutics Inc traded for a price of $2.18 per share and a market cap of $43,392,000. The stock has returned -64.32% over the past year.

GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, F-star Therapeutics Inc has a price-book ratio of 0.44, a EV-to-Ebitda ratio of 0.70 and a price-sales ratio of 1.71.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.

Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles